New liver Drug's safety check: can it mix with hepatitis b antivirals?
NCT ID NCT07295873
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This early-stage trial will test a new drug called hydronidone, which is being developed for liver fibrosis caused by hepatitis B. Since patients often need to take antiviral drugs for hepatitis B, researchers want to see if hydronidone can be taken safely alongside four common antivirals. The study involves 64 healthy Chinese adults and will measure how the drugs interact in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hydronidone
- What this could lead to
- If successful, this study will show that hydronidone can be safely taken alongside common hepatitis B antivirals, paving the way for a combination treatment for liver fibrosis.
- What could go wrong
- This is an early Phase 1 trial in only 64 healthy people, not patients. It only checks drug interactions, not whether hydronidone actually treats liver fibrosis. Side effects may still emerge.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B LIVER FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Gaobo Hospital
Beijing, 100000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.